Nov 13, 2020

# Santen to Present Latest Data on Omidenepag Isopropyl and Microshunt at AAO 2020 Virtual

Santen Pharmaceutical Co., Ltd. (Head Office in Osaka) announced today that some publications related to EP2 receptor agonist omidenepag isopropyl and the glaucoma surgical device, microshunt will be presented at the American Academy of Ophthalmology's annual meeting (AAO 2020 Virtual) from November 13 to 15, 2020.

Omidenepag isopropyl was launched in Japan in 2018 as *EYBELIS Ophthalmic Solution 0.002%*, a treatment for glaucoma and ocular hypertension. It has been approved in several Asian countries, including the Republic of Korea, and is being developed in the United States (development code: DE-117, STN10117). At this conference, the interim data of post-marketing observational study in Japan (lecture number PA020) is being presented. In addition, data from the Phase 2/3 trial, INN-005 of the glaucoma surgical device, microshunt, which has been launched in Europe as *PRESERFLO MicroShunt* and is being developed in the United States, are also published (development code: DE-128, STN20001).

Presentation topics related to omidenepag isopropyl and microshunt

| Session number | Presentation title |
|---|---|
| PA020<br>/ Paper | Safety and Efficacy of Omidenepag Isopropyl, an EP2 Agonist, in Multicenter Observational Study in Japan: Interim Results |
| PO178<br>/ ePoster | Randomized Phase 2 Trial Assessing the Safety and Efficacy of Omidenepag Isopropyl 0.002% Once and Twice Daily |
| PD01V<br>PO189<br>/ ePoster | One-Year Safety and Effectiveness of Microshunt vs. Trabeculectomy in Sites in the USA and Europe in a Randomized Study<br>Poster Discussion: 1:00PM -1:30PM PST, November 14, 2020 |
| PO193<br>/ ePoster | Safety Outcomes of Microshunt Implantation vs. Trabeculectomy in Patients With POAG |

Contact:
Investor Relations Group
Santen Pharmaceutical Co., Ltd.
E-mail: ir@santen.com